Document is current
Any future updates will be listed below
-
Authors
Wedel, Saskia
Mathoor, Praveen
Rauh, Oliver
Heymann, Tim
Ciotu, Cosmin I.
Fuhrmann, Dominik C.
Fischer, Michael J. M.
Weigert, Andreas
de Bruin, Natasja
Hausch, Felix
Geisslinger, Gerd
Sisignano, Marco
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB1039 A09, SFB1039 B06, SFB1039 Z01)
Bundesministerium für Bildung und Forschung (51TaValP)
European Research Council (ERC; 2015 Advanced Grant 495 (AdG) n. 695078 noMAGIC)
Fraunhofer Cluster of Excellence for Immune-Mediated Diseases
Johann Wolfgang Goethe-Universität, Frankfurt am Main
- License Information
-
More Information
Article History
Received: 11 August 2022
Accepted: 4 October 2022
First Online: 10 October 2022
Declarations
:
: All experiments involving animals were approved by the local Ethics Committee for Animal Research (Darmstadt) under the permit number F152/1021. Furthermore, all animal experiments were performed according to the recommendations of the Preclinical Pain Research Consortium for Investigating Safety and Efficacy (PPRECISE) Working Group [], according to the updated ARRIVE guidelines for reporting animal research [] and guidelines as defined by European Quality In Preclinical Data (EQIPD) []. All efforts were made to minimize animal suffering.
: Not applicable.
: The authors declare that they have no competing interests.
